• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

EZH2 Methyltransferase Inhibitors Hold Promise for Combating Neuropathic Pain

by Bellbrook Labs / Friday, 21 July 2017 / Published in Emerging Targets, Epigenetics, HTS Assays

When people experience neuropathic pain, they often describe “pins and needles” sensations or burning, shooting, or stabbing pain that can be agonizing and difficult to bear. In some cases, neuropathic pain is so intense that the pressure of clothing or the weight of a bed sheet can cause misery. Chronic neuropathic pain can be caused by conditions such as diabetes, shingles, HIV/AIDS, chemotherapy, amputation (“phantom limb” syndrome), multiple sclerosis, or back injury. An estimated 6.9 to 10 percent of the population experiences neuropathic pain,[1] and the global market for drugs to treat neuropathic pain was $5.2 billion in 2015 and is expected to reach $8.3 billion by 2024.[2]

EZH2 Methyltransferase Spotlight on Neuropathic PainNew approaches to treating neuropathic pain are urgently needed—particularly non-opioid agents. In this light, recent research on Enhancer of zeste homolog 2 (EZH2) has been of interest. EZH2 is a histone methyltransferase that is the catalytic subunit of the Polycomb repressive complex 2 (PRC2). This enzyme elicits transcriptional silencing by acting on histone H3 at lysine 27 (H3K27) to generate trimethylated H3K27 (H3K27me3), and also is known to be involved in Wnt/beta-catenin and Notch signaling. Two different research teams have recently published animal model and cell line data indicating that EZH2 activity is a key regulator in the development of neuropathic pain. The teams found that inhibition of EZH2 provides analgesia and reduces markers of neuroinflammation in cell lines and in rats.[3][4]

In the animal study, Yadev et al. used an established model of neuropathic pain (partial sciatic nerve ligation), confirming that both EZH2 expression and trimethylation of lysine 27 increased in the region of the spinal dorsal horn affected by the ligation procedure.3 This area of the spinal dorsal horn is involved in the genesis of neuropathic pain. Conversely, local administration of the EZH2 inhibitors 3-Deazaneplanocin (DZNep) or GSK126 attenuated pre-existing neuropathic pain (as measured by behavioral tests) and decreased expression of EZH2 and methylation of H3K27. The researchers also found that the EZH2 inhibitors blocked activation of microglia, the resident immune cells in the central nervous system, and reduced the levels of several markers of neuroinflammation including TNF-alpha, IL-1beta, and MCP-1. Altogether, the results led the team to conclude that EZH2 inhibitors pose “a novel strategy for the development of new analgesics for the treatment of neuropathic pain.”3

In the second study, Arifuzzaman et al. investigated whether inhibition of EZH2 with the selective small molecule inhibitor EPZ-6438 would protect against microglial activation in mouse microglial primary cells and a microglial cell line.4 EPZ-6438 is currently in Phase II human clinical trials for treatment of non-Hodgkin Lymphoma.[5].  The researchers conducted RNA-Seq analysis of the transcriptomes of resting, EPZ-6438-treated, LPS-treated and LPS + EPZ-6438-treated primary microglial cells and an immortalized murine microglial cell line (BV-2).4 While expected EPZ-6438 target genes and co-regulated networks were confirmed, the data also indicated unexpected effects of EPZ-6438 on inducible transcription factors and regulation of important inflammatory mediators by EZH2. Additionally, Arifuzzaman et al. found evidence that EPZ-6438 affects inflammatory gene targets via IRF1, IRF8, and STAT1.

By developing a greater understanding of the mechanism action of EPZ-6438 for anti-neuroinflammatory activity, researchers hope that it will lead to new approaches for treating a host of neurological diseases. For people living in chronic neuropathic pain, relief in the form of new therapeutic agents can’t come soon enough. But considering that microglial activation also plays a role in many other conditions including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, rheumatoid arthritis, and some breast cancers, identifying new EZH2 inhibitors using biochemical EZH2 Assays and characterizing known inhibitors could have broad implications indeed.

– Robyn M. Perrin, PhD

View BellBrook’s Methyltransferase Assays

[1] van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. 2014. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 155(4):654-62.

[2] “Global Neuropathic Pain Market to Reach US$ 8.3 Bn by 2024 End,” November 29, 2016. http://www.persistencemarketresearch.com/mediarelease/neuropathic-pain-market.asp

[3] Yadav R, Weng HR. 2017. EZH2 regulates spinal neuroinflammation in rats with neuropathic pain. Neuroscience. 349:106-117.

[4] Arifuzzaman S, Das A, Kim SH, Yoon T, Lee YS, Jung KH, Chai YG. 2017. Selective inhibition of EZH2 by a small molecule inhibitor regulates microglial gene expression essential for inflammation. Biochem Pharmacol. 137:61-80.

[5] A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma. https://clinicaltrials.gov/ct2/show/NCT02601950

Tagged under: AptaFluor SAH Methyltransferase Assay, Assay Development Services, EPIGEN Methyltransferase Assay, Lead Discovery Services, methyltransferase

What you can read next

B4GalT1 A Target to Stop Glioblastoma
B4GalT1 – A Druggable Target for the Treatment of Glioblastoma
ADP Detection: It’s not all about kinases
PDE Activity Assay Heart Disease
How A PDE Activity Assay Might Help Find New Treatments for Individuals Suffering from Heart Disease

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP